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Abstract
Malignant gliomas are highly infiltrative and invasive tumors, which precludes the few treatment options available.
Therefore, there is an urgent need to elucidate the molecular mechanisms underlying gliomas aggressive phenotype and
poor prognosis. The Raf Kinase Inhibitory protein (RKIP), besides regulating important intracellular signaling cascades, was
described to be associated with progression, metastasis and prognosis in several human neoplasms. Its role in the prognosis
and tumourigenesis of gliomas remains unclear. In the present study, we found that RKIP protein is absent in a low
frequency (10%, 20/193) of glioma tumors. Nevertheless, the absence of RKIP expression was an independent prognostic
marker in glioma. Additionally, by in vitro downregulation of RKIP, we found that RKIP inhibition induces a higher viability
and migration of the cells, having no effect on cellular proliferation and angiogenesis, as assessed by in vivo CAM assay. In
conclusion, this is the largest series studied so far evaluating the expression levels of this important cancer suppressor
protein in glioma tumors. Our results suggest that in a subset of tumors, the absence of RKIP associates with highly
malignant behavior and poor survival of patients, which may be a useful biomarker for tailored treatment of glioma
patients.
Citation: Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Gonc¸alves V, et al. (2012) Downregulation of RKIP Is Associated with Poor Outcome and
Malignant Progression in Gliomas. PLoS ONE 7(1): e30769. doi:10.1371/journal.pone.0030769
Editor: Chris Jones, Institute of Cancer Research, United Kingdom
Received July 21, 2011; Accepted December 21, 2011; Published January 23, 2012
Copyright:  2012 Martinho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was partially funded by the Fundac¸a˜o para a Cieˆncia e Tecnologia, Portugal (PTDC/SAU-TOX/114549/2009). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rreis@ecsaude.uminho.pt
Introduction
Gliomas are the most frequent primary brain tumors and
include a variety of different histological tumor types and World
Health Organization (WHO) malignancy grades. Histologically,
astrocytic, oligodendroglial, and mixed oligoastrocytic tumors are
the most relevant gliomas [1–3]. Low-grade (WHO grade II)
diffuse astrocytomas have an invariably tendency for malignant
progression to anaplastic (WHO grade III) astrocytomas and
eventually to glioblastomas (WHO grade IV) – the most aggressive
and frequent subtype [4]. So far, histopathology is the gold
standard for the typing and grading of gliomas; however additional
biological markers are needed for an advanced and more objective
glioma classification, for a better prediction of prognosis and more
targeted a tailored therapeutic decision-making. In this regard, to
date the number of biomarkers used in neurooncology routine are
rather limited to combined deletions of the chromosome arms 1p
and 19q in oligodendroglial tumors, MGMT hypermethylation in
glioblastomas and IDH1 mutations in diffuse gliomas [5–7].
Raf Kinase Inhibitory Protein (RKIP; also known as PEBP1, for
phosphatidylethanolamine-binding protein 1), is a widely expressed
protein in normal human tissues, emphasizing its role in various
physiologic processes [8,9]. Functionally, it is an intracellular
regulator of important signaling pathways such as RAF/MEK/
ERK, G-protein–coupled receptor kinase-2, nuclear factor Kappa
B (NFkB) and GSK3b transduction pathways [10–13]. Likewise,
RKIP has been shown to be a multifunctional protein in
carcinogenesis, being implicated in various intracellular signaling
pathways that control cellular growth [14,15], motility [16,17],
epithelial to mesenchymal transition (EMT) [18], differentiation
[19], invasion and tumor metastisation [20,21]. Initial reports have
termed RKIP, as a metastasis suppressor gene, due to its paramount
in the metastisation of processes of several neoplasms including
melanomas and prostate [9,22–24]. Further studies have shown that
RKIP role is tumor-type specific, and in most cancer types, such as
colorectal carcinoma, gastric adenocarcinoma, hepatocellular
carcinoma, and GISTs loss of RKIP expression is linked to
advanced tumor stages and worse clinical outcome [25–32].
With regard to RKIP expression in gliomas, two groups have
reported a correlation between RKIP downregulation and higher
tumor grade [28,33]. Maresch et al, also suggested that RKIP
expression is a marker of good prognosis in high-grade gliomas
[28]. Nevertheless, the biological role of RKIP in the malignant
progression of gliomas remains to be elucidated.
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In the present work, using a large series of gliomas, we aimed
first to clarify the frequency of RKIP expression and to validate its
role in the prediction of clinical outcome in patients with glioma.
Secondly, we aimed to assess, in vitro and in vivo, the biological
consequences of RKIP downregulation on aggressiveness of glial
tumors.
Results
Characterization of RKIP expression in glial tumors
In the present study, 193 gliomas and 18 normal brain tissues
(12 were non-neoplastic brain tissues adjacent to the tumor) were
studied for RKIP immunohistochemical expression. RKIP
positivity was found in the cytoplasm of the great majority of
samples (Figure 1), however, nuclear expression was also
observed in a few cases (mainly low grade astrocytomas). We
observed that RKIP was highly expressed (Figure 1A) in all the
18 non-neoplastic brain tissues studied. In general, RKIP
expression was found in 89.6% (20/193) of all the tumors,
specifically in 95.2% (20/21) of astrocytomas grade II
(Figure 1B), in 89.5% (128/143) of glioblastomas (Figure 1E
and F), in 80% (12/15) of oligodendrogliomas grade II
(Figure 1C and D), 75% (3/4) of anaplastic oligoastrocytoma,
and 100% of oligoastrocytomas grade II (2/2) and anaplastic
oligodendrogliomas (8/8) (Table 1).
No significant associations were found between RKIP
expression and clinical pathological data such as age, gender,
cellular lineage, histological type and malignancy grade (Table 1).
However, it was found a significant (p=0,004) higher number of
RKIP negative cases in the subgroup of patients that were no
treated with adjuvant therapy (temozolomide plus radiotherapy)
(Table 1). By univariate analysis, we found a significant
association (p=0.033) between absence of RKIP expression and
poor prognosis in gliomas (Figure 2). When the tumors were
stratified by malignant grade, the association was only substan-
tiated for the patients with high grade tumors (p=0.025). When
considering only the glioblastoma patients, the correlation
approached significance (p=0.096). Additionally, when we
stratified the patients for RKIP expression and treatment
simultaneously no differences were obtained between the survival
of the two groups (treated vs no treated) of patients (p,0.05).
Following multivariate analysis, we observed that the absence of
RKIP expression is an independent prognostic marker for
gliomas (p=0.027). Additionally, age and malignancy grade were
also independent prognostic markers in this cohort of glioma
patients (Table 2).
Figure 1. Immunohistochemistry analysis of RKIP in gliomas. A)
Normal brain and B) astrocytoma grade II showing high expression. C)
Positive and D) Negative expression in oligodendroglioma grade II. E)
Positive and F) Negative expression in glioblastoma. All the pictures
were taken with at 2006magnification.
doi:10.1371/journal.pone.0030769.g001
Table 1. RKIP expression in gliomas and associations with
patients clinicopathological data (n = 193).
Parameter
RKIP Expression
(N=193)
N
Negative
(%)
Positive
(%) p value
Age (years)
$50 89 10 (11.2) 79 (88.8) 0.801
,50 99 10 (10.1) 89 (89.9)
Gender
Male 117 13 (11.1) 104 (88.9) 0.672
Female 76 7 (9.2) 69 (90.8)
Cellular Lineage
Astrocytic 164 16 (9.8) 148 (90.2) 0.779
Oligodendroglial 23 3 (13) 20 (87)
Mixed 6 1 (16.7) 5 (83.3)
Histological type (WHO grade)
Diffuse astrocytoma (II) 21 1 (4.8) 20 (95.2) 0.508
Glioblastoma (IV) 143 15 (10.5) 128 (89.5)
Oligodendroglioma (II) 15 3 (20) 12 (80)
Anaplastic
oligodendroglioma (III)
8 0 (0) 8 (100)
Oligoastrocytoma (II) 2 0 (0) 2 (100)
Anaplastic oligoastrocytoma (III) 4 1 (25) 3 (75)
Malignancy grade (WHO)
Low-grade (II) 38 4 (10.5) 34 (89.5) 0.971
High-grade (III, IV) 155 16 (10.3) 139 (89.7)
Treatment with TMZ+RT
No 71 13 (18.3) 58 (81.7) 0.004
Yes 66 2 (3.0) 64 (97.0)
Follow-up (mean months 6 SD)
Gliomas 181 19.266.2 52.067.9 0.033
Low-grade Gliomas 31 46.3620.4 131.7620.7 0.317
High-grade Gliomas 150 9.961.5 23.463.3 0.025
Glioblastomas (WHO IV) 138 10.561.5 16.961.2 0.096
N: Number of cases; SD: Standard deviation; WHO: World Health Organisation;
p: person X2 value; TMZ: Temozolomide; RT: Radiotherapy.
doi:10.1371/journal.pone.0030769.t001
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Effect of RKIP on glioblastoma cell biological behavior in
vitro
To further explore the biological role of RKIP in glioblastoma
cells, we first characterized the expression of RKIP in a panel of 8
glioblastoma cell lines. To observe the distribution of RKIP
expression at the cellular level, we performed immunocytochem-
istry in all the glioblastoma cell lines. We observed that RKIP was
present in all and the expression pattern was mainly cytoplasmatic
and sometimes nuclear, mainly in mitotic cells (Figure 3A). By
western blot analysis (Figure 3B), we confirm that all cell lines
express RKIP, however at different levels. Next, we proceeded
with the in vitro knockdown of RKIP using a specific short hairpin
RNA (shRKIP) in the U251 cell line. As shown in Figure 3C,
RKIP protein levels were downregulated in the shRKIP
transfected cells in comparison with the cells transfected with the
control empty vector. Since RKIP is considered to be an
Figure 2. Disease-specific survival (DSS) according to RKIP expression in gliomas (n=181). Cumulative survival is significantly lower in
cases with RKIP loss of expression (p = 0.033).
doi:10.1371/journal.pone.0030769.g002
Table 2. Independent prognostic factors in gliomas.
Parameter Univariate Analysis Multivariate Analysis
N (months ± SD) p HR (95% CI) p
Malignancy grade (WHO)
Low-grade (II) 31 125.3619.7 1
High-grade (III, IV) 150 22.162.9 ,0.001 4.9 (2.5–9.6) ,0.001
Age (years)
,50 94 66.4610.6 1
$50 87 16.961.9 ,0.001 1.5 (1.01–2.2) 0.040
RKIP expression
Positive 162 52.067.9 1
Negative 19 19.266.2 0.033 1.8 (1.1–3.1) 0.027
HR: Hazard ratio, 95% CI: 95% Confidence interval.
doi:10.1371/journal.pone.0030769.t002
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endogenous inhibitor of the Raf-1/MEK/ERK pathway we
evaluated whether RKIP inhibition on glioblastoma cells modu-
lates this pathway. As showed in Figure 3C, RKIP downregulated
cells presented increased phosphorylation levels of ERK when
stimulated with EGF, however it seems no to be significant.
Concerning the biological assays, we first evaluated the effect of
RKIP inhibition on glioblastoma cells viability over the time
(Figure 4A). We found that at 72 hours the empty vector cells loose
viability, while RKIP inhibited cells remained viable with a
statistically significant difference (p,0.05). To evaluate whether
RKIP modulates rate of cell cycle transit, we determined the cell
cycle scattering of the transfected cells. As observed in Figure 4B,
no statistically significant differences were found in the cell cycle
scattering of shRKIP and empty vector cells.
In order to study the effect of RKIP on glioblastoma cellular
migration we performed a wound healing assay (Figure 4D). We
found that RKIP downregulated cells migrate significantly
(p,0.05) more than control cells, both at 24 and 72 hours
(Figure 4C).
In vivo role of RKIP expression in glioblastomas
To evaluate the effect of RKIP-mediated tumor growth and
angiogenesis in vivo, we performed a CAM assay. The U251
transfected cells were implanted into the CAM of the chick
embryo (empty vector cells, n = 7; shRKIP cells, n = 11), and seven
days after cell implantation, the chicken embryos were sacrificed to
evaluate tumor growth and angiogenesis ex ovo (Figure 5A). The
mean perimeter of the tumors formed by the control and the
shRKIP U251 transfected cells was 5820.561265.3 mm and
6108.561005.7 mm, respectively, with no statistically significant
differences (Figure 5B, upper panel).
To evaluate the impact of RKIP on angiogenesis, we counted ex
ovo the number of vessels around the tumors. The mean of 1965
and 1864 vessels in the tumors formed by the empty vector and
the shRKIP transfected cells, respectively (Figure 5B, lower panel),
was not statistically significant.
Discussion
Diffusely infiltrating gliomas are one of the most devastating
cancers because they often show locally aggressive behavior and
cannot be cured by existing therapies [4]. Like cancer in general,
gliomas develop as a result of genetic alterations that accumulate
throughout tumor progression [1–3]. Therefore, the elucidation of
these molecular mechanism, in particular the one associated with
cellular migration and invasion are crucial for a better prediction
of glioma patients outcome and response to therapies [34].
RKIP protein is an important regulator of tumor cell invasion
and metastasis [9,22–24]. Furthermore, was reported to be a
prognostic biomarker for a number of tumors including prostate,
colorectal, GISTs, gastric adenocarcinoma of the intestinal
Figure 3. RKIP expression in glioma cell lines. A) Immunocytochemistry analysis of RKIP in glioma cell lines cells with both nuclear and
cytoplasmic expression. B) Western blot analysis confirming the expression of RKIP at different levels in glioma cell lines. C) For RKIP inhibition, U251
cells were stably transfected with a shRNA for RKIP and with the respective empty vector for control. The band densitometry analysis showed that the
shRKIP transfection induced a reduction of around 50% of the protein levels in relation to the control cells. Further, the cells were stimulated with
50 ng/ml of EGF by 10 minutes and ERK pathway activation was assessed by western blot for phospho-ERK1/2 expression. ERK pathway was
overactivated in shRKIP transfected cells after EGF stimulation. Quantification of western blot results, using the band densitometry analysis, was
performed with Image J software. For RKIP relative protein expression results are shown as the ratio between RKIP and b-Actin and for ERK activity
the results are shown as the ratio between p-ERK1/2 and total ERK1/2.
doi:10.1371/journal.pone.0030769.g003
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subtype, hepatocellular carcinoma, pancreatic ductal adenocarci-
noma and also in high grade gliomas [25–32]. Thus, in the present
work, our goal was to evaluate the prognostic value of RKIP in
glioma patients’ and assessed its biological impact on gliomagen-
esis by in vitro and in vivo assays.
By immunohistochemistry analysis in 193 glioma tumors, we
found that RKIP protein was highly expressed in all the non-
neoplastic brain samples, and also in the great majority of glioma
tumors with 89.6% (173/193) of positively stained cases. No
significant correlations were found when the cases were stratified
by age, gender, cellular lineage, histological type and malignancy
grade. Our results are partially divergent with previous reports
that described a correlation between loss of RKIP expression and
higher malignant grade [28,33]. By proteomic analysis in 15 cases
(5 astrocytomas grade II, 5 grade III and 5 grade IV), Gimenez
and colleagues described RKIP as one of the proteins that is
downregulated in high grade when compared to low-grade
tumors [33]. However the low number of cases may account for
the discrepancy with our study. Maresch et al, in a recent
publication using 159 gliomas, found that RKIP is present in
82% (22/27) of low-grade astrocytomas and only in ,53% (67/
126)of high grade gliomas, and the difference was statistically
significant [28]. Despite using the same antibody for the
immunohistochemistry analysis, the authors used a different set
of criteria for scoring results. They counted a case as positive only
when 90% of the cells showed moderate to strong cytoplasmic
staining [28], which may outcome in false negative cases and
account for the discrepancy with our data. This discrepancy was
observed mainly for high grade gliomas that are heterogeneous
tumors for which the immunohistochemistry classification has to
take into account both extent and intensity of the staining.
Noteworthy, the criteria used in our study, was the same as those
used in the major reports on RKIP immunohistochemistry
expression that should be used for comparison studies [21,31,35].
Nevertheless, Maresch et al found an association between loss of
RKIP expression and poor prognosis of high-grade glioma
patients, consistent with our findings in the present work.
Moreover, in our work we propose RKIP as an independent
prognostic marker for gliomas.
RKIP is widely expressed in normal human tissues and has been
studied for several years as an important regulator of several
physiologic processes [9]. In the central nervous system, RKIP is
present in several regions of the brain and its downregulation is
associated with deregulation of neurological homeostasis, being
mainly implicated in Alzheimer disease [8]. Its specific function in
brain tumors development is unknown.
Figure 4. In vitro role of RKIP in U251 cells biological behavior. A) The cellular viability was measured at 24, 48 and 72 hours by MTS. RKIP
inhibited cells had a viability advantage at 72 hours, when compared to control cells. B) Cell cycle analysis was done at 24 hour time point by flow
cytometric analysis of propridium iodide stained cells. No differences were found in the cell cycle distribution. C) In the wound healing migration
assay, a standardized scratch (wound) was applied to monolayers and digital images were taken at several time points (0, 24 and 72 hours). We
observed that shRKIP transfected cells had a migration advantage at 24 and 72 hours. D) Representative images of the assay at 0 and 72 hours are
represented (406 magnification). All the experiments were done in triplicate at least three times. Data is represented as the mean 6 SD and
differences with a p,0.05 on the Student’s t test were considered statistically significant (*).
doi:10.1371/journal.pone.0030769.g004
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To understand the biological role of RKIP downregulation in
glioblastomas, we performed an in vitro and in vivo study with the
U251 cell line transfected with a specific shRNA for RKIP. We
observed in vitro that RKIP inhibited cells had a viability advantage
at 72 hours when compared with cells with normal levels of RKIP.
However, the cell cycle analysis did not disclose significant
differences on the cell cycle distribution between shRKIP and
empty vector cells, and in vivo, it did not also disclosed differences
in the proliferation rates of the tumors produced by both
transfected cells. Those results suggested that RKIP has no effect
on glioblastoma proliferation, being the effect that we are seeing in
the MTS assay a reflection of an increased metabolic activity of
the cells or a decrease on cellular apoptosis. RKIP expression is
negatively regulated by SNAIL [36], thus permitting enhanced
NF-kB signaling resulting in a circuitry that regulates both the
metastatic cascade and resistance to apoptosis by cytotoxic drugs
[37]. Thus, loss of RKIP expression in cancers can result in a
dramatic inhibition of apoptosis and the development of
chemoresistance [38–40]. The role of RKIP in glioma cells
apoptosis at basal conditions, without a cytotoxic stress, has to be
elucidated in the future.
Additionally, we found in vitro that downregulation of RKIP
significantly increased cellular migration, but no differences were
observed in the in vivo vascularization of the tumors formed by
both shRKIP and empty vector cells. These results suggest that
RKIP can be an important promoter of glioblastoma cells
migration, but has no effect in tumoral angiogenesis.
Our present findings are in accordance with previous reports in
other types of tumors, where RKIP seems to be more important in
migration of the cells, instead of as a proliferation suppressor
[16,21,41–43]. Concerning angiogenesis, our results are distinct
from reports on breast and prostate cancer mouse models, where
RKIP overexpression is described as decreasing angiogenesis and
vascular invasion [20,21].
In conclusion, we herein substantiate, in the largest series
studied so for, that loss of RKIP expression is an independent
marker of poor clinical outcome in glioma patients. Despite the
small number of RKIP negative cases, we found, by in vitro and in
vivo evaluation, that RKIP inhibition is mainly associated with
higher migration of glioblastoma cells. Altogether, our results
suggest that in addition to its prognosis value, RKIP can be
considered a modulator of the malignant phenotype in glioblas-
tomas.
Materials and Methods
Tissue samples
Representative formalin-fixed paraffin-embedded blocks from
193 consecutive neurosurgeries performed due to glioma were
retrieved from pathology archives of the Department of Pathology
of Hospital S. Joa˜o, Porto and Hospital Pedro Hispano,
Matosinhos. The tumors were classified according to the WHO
criteria [1]. This cohort includes 164 astrocytic, 23 oligodendrog-
lial and 6 oligoastrocytic tumors of diverse malignant grades
(Table 1). The mean age of patients at diagnosis was 50615
(range, 2–77 years), with a female/male ratio of 0.65. Follow-up
data was available in 181 patients (range: 0–210 months, mean:
22.1628.0 months). For 137 glioblastomas we had available
information regarding patients’ treatment with adjuvant therapy
(temozolomide plus radiotherapy) (Table 1).
Figure 5. In vivo role of RKIP in U251 cells growth and angiogenesis. A) Representative pictures (166magnification) of CAM assay after 7
days of tumor growth in ovo and ex ovo. B) Tumor growth was measured in vivo by CAM assay as described in materials and methods section. We
observed a larger perimeter (mM) in the tumors formed by U251 shRKIP cells, there was no significant difference from control cells (upper panel). The
counting of the blood vessels ex ovo revealed no differences in the number of vessels recruited in the tumors formed by shRKIP cells when compared
to the control (lower panel). We analyzed 18 eggs (7 were injected with empty vector and 11 with shRKIP U251 transfected cells). The data is
represented as the mean 6 SD and differences with a p,0.05 on the Student’s t test were considered statistically significant.
doi:10.1371/journal.pone.0030769.g005
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Cell lines and cell culture procedures
In the present study we used 8 glioblastoma cell lines. The cell
lines SW1088, SW1783, U87-MG and A172 were obtained from
ATCC (American Type Culture Collection), the cell lines SNB-19
and GAMG were obtained from DSMZ (German Collection of
Microorganisms and Cell Cultures) and the cell lines U251 and
U373 were kindly provided by Professor Joseph Costello,
California University, Neurosurgery Department, San Francisco,
USA. All cell lines were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM 16, High Glucose; Gibco, Invitrogen)
supplemented with 10% Fetal Bovine Serum (FBS; Gibco,
Invitrogen) and 1% penicillin/streptomycin solution (Gibco,
Invitrogen), at 37uC and 5% CO2.
Immunohistochemistry and immunocytochemistry
analysis of RKIP
Representative 3 mm-thick tissue sections were used to immu-
nohistochemical analysis according to the streptavidin-biotin
peroxidase complex system (UltraVision Large Volume Detection
System Anti-Polyvalent, HRP; LabVision Corporation), as
previously described [32,44]. Briefly, deparaffinised and rehydrat-
ed slides were submitted to heat-induced antigen retrieval for
20 minutes at 98uC with 10 mM citrate buffer (pH 6.0). After
incubation with the primary antibody raised against RKIP
(dilution 1:600 incubation 1H at RT; Upstate Biotechnology),
the secondary biotinylated goat anti-polyvalent antibody was
applied for 10 minutes followed by incubation with the strepta-
vidin-peroxidase complex. The immune reaction was visualized by
3,39-Diamonobenzidine (DAB) as a chromogen. All sections were
counterstained with Gill-2 haematoxylin. For negative controls,
primary antibodies were omitted and also replaced by a universal
negative control antibody (CEA, rabbit anti-human, DAKO
Corporation). A prostate carcinoma was used as positive control.
Sections were scored double-blind (by JML and OM) for
cytoplasmic expression following a semi-quantitative criterion, by
comparison with (internal/external) positive and negative controls
included in each run. The score used was the sum of the percentage
of positive cells (0, negative; 1, less than 25% positive cells; 2, 26% to
50% positive cells; and 3, more than 50% positive cells) and the
staining intensity (0, negative; 1, weak; 2, moderate; 3, strong).
Scores between 0 and 2 were classified as negative, 3 and 4 as
moderate positive, and 5 and 6 as strongly positive [32,44].
Controversial cases were re-evaluated and classified by consensus.
For RKIP immunocytochemical analysis of glioma cell lines, the
cells were plated on glass coverslips placed into 12-well plates, and
allowed to adhere overnight. Then, the cells were fixed in
paraformaldehyde at 4% for 15 minutes, followed by permeabi-
lization with 0.05% Triton X-100 for 4 minutes at room
temperature. The immunocytochemistry procedure was per-
formed using a streptavidin-biotin peroxidase complex method
as described above.
Generation of a shRKIP stably expressing cell line
For generation of a glioma cell line stably expressing shRKIP,
we used the PQY15 vector, containing a 19 bp shRNA for RKIP,
as previously described [45,46]. The transfection was done using
the FUGENE HD reagent (Roche) as recommended by the
manufacture, with 2 mg of plasmid at a ratio of 6:2 (Reagent:-
Plasmid). The cells (1.56105) were plated onto a 12-well plate until
80% confluence and transfected in DMEM medium, without FBS
or antibiotics addition, for 24 hours. Then, the stable transfectants
were selected with 1 mg/ml of puromycin in complete DMEM
medium. The empty vector was also transfected as control.
Western blot analysis
The cells were plated in a 6 well plate at a density of 56105
cells per well and allowed to adhere at least 24 hours. The cells
were serum starved for 6 hours before protein isolation. When
necessary the cells were also stimulated with 50 ng/ml of EGF for
10 minutes before the end of the 6 hours of starvation. Cells were
scraped in cold PBS and lysed in buffer containing 50 mM Tris
pH 7.6–8, 150 mM NaCl, 5 mM EDTA, 1 mM Na3VO4,
10 mM NaF, 10 mM NaPyrophosphate, 1% NP-40 and 1/7 of
Protease cocktail inhibitors (Roche). Western blotting was done
using standard 12% SDS-PAGE gel, loading 20 mg of protein per
lane, with detection by enhanced chemiluminescence (Super-
Signal West Femto Maximum Sensivity Substrate, Pierce). RKIP
expression was evaluated using a specific antibody against RKIP
(dilution 1:2000, Upstate Biotechnology). Activated ERK was
assessed using the antibody phospho-p44/42 MAPK (Thr202/
Tyr204) (dilution 1:1000, Cell Signaling Technology). The total
form of ERK was also assessed with the antibody p44/42 MAPK
(Erk1/2) (137F5) (dilution 1:1000, Cell Signaling Technology).
For a loading control we used b-Actin (dilution 1:300, Santa Cruz
Biotechnology). All the primary antibodies were incubated
overnight at 4uC. Quantification of western blot results using
the band densitometry analysis was performed with Image J
software.
Cell viability assay
The cells were plated into 96-well plates in triplicate at a density
of 16103 cells per well and allowed to adhere overnight in
complete DMEM medium. After 6 hours of serum starvation the
viable cells were quantified using Cell Titer96 Aqueous cell
proliferation assay (Promega), and used as time 0 of the
experience. Then, cells were incubated in DMEM medium
without serum for 24, 48 and 72 hours and cell viability was
again assessed by Cell Titer96 Aqueous cell proliferation assay.
The results were calibrated to the starting viability (time 0 h,
considered as 100% of viability) and expressed as the mean 6 SD.
The assay was performed in triplicate at least three times.
Wound healing migration assay
The cells were seeded in 6-well plates and cultured to at least
95% of confluence. Monolayer cells were washed with PBS and
scraped with a plastic 200 mL pipette tip and then incubated with
fresh DMEM medium without FBS. The ‘‘wound’’ areas were
photographed by phase contrast microscopy at 0, 24 and
72 hours’ time points. The relative migration distance was
calculated by the following formula: percentage of wound closure
(%) = 100 (A–B)/A, where A is the width of cell wounds before
incubation (0H), and B is the width of cell wounds after
incubation. Results are expressed as the mean 6 SD. The assay
was done in triplicate at least three times.
Cell cycle analysis
The cells were plated in a 6-well plate at a density of 26105 cells
per well and allowed to adhere overnight. After 6 hours of serum
starvation the cells were incubated with fresh DMEM medium
without serum during 24 hours. Cells were trypsinized and fixed in
70% ethanol for at least 30 minutes and then stained for 1 hour at
50uC with propidium iodide (PI) solution (20 mg/mL of PI and
250 mg/mL of RNAse in a solution of 0.1% Triton X-100 in PBS).
Cell cycle analysis of the PI stained cells was performed by flow
cytometry (LSRII, BD Biosciences). The percentage of cells in
each phase of the cell cycle was determined with the software
FlowJo version 7.6.3. The results were expressed as the mean 6
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SD of the percentage of cells in G1 phase or G2/M plus S phase.
The assay was done in triplicate at least three times.
Chick chorioallantoic membrane (CAM) assay
To assess in vivo tumor proliferation and angiogenesis we used
the CAM assay as previously described [47], with some brief
modifications. Fertilized chicken eggs were incubated at 37uC and
70% humidity, and on day 3 of development, a window was made
into the shell, which was sealed with tape, and the eggs were
returned to the incubator. On day 9 of development, small plastic
rings were placed on the CAM and on day 10 of development
36106 cells, ressuspended in 20 ml of DMEM medium, were
injected in the rings over the CAM. On day 17 of development,
the tumor formed was photographed in ovo using a stereomicro-
scope (Olympus S2x16). The chickens were sacrificed at 280uC
for 10 minutes, and the CAM and tumors were fixed with
paraformaldehyde at 4% and photographed ex ovo. The perimeter
of the tumors was measured using Cell B software (Olympus), and
blood vessels were manually counted.
Statistical analysis
Correlations between RKIP expression and clinical data of the
patients were performed using the chi-square test (x2-test).
Cumulative survival probabilities were calculated using the
Kaplan-Meier method. Differences between survival rates were
tested using the log-rank test. Multivariate analysis was done using
the Cox proportional hazards model. The statistical analysis was
performed using SPSS software for Windows, version 17.0.
For in vitro assays, single comparisons between the different
conditions studied were done using Student’s t test. Statistical
analysis was done using Graph Pad Prism version 5. The level of
significance in all the statistical analysis was set at p,0.05.
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